Endocrinology, Hormone Replacement Therapy (HRT), and Aging

@article{Houlberg2019EndocrinologyHR,
  title={Endocrinology, Hormone Replacement Therapy (HRT), and Aging},
  author={Magda Houlberg},
  journal={Transgender and Gender Nonconforming Health and Aging},
  year={2019}
}
  • M. Houlberg
  • Published 2019
  • Medicine
  • Transgender and Gender Nonconforming Health and Aging
Hormone replacement therapy (HRT) protocols for older transgender and gender nonconforming (TGNC) people are based on existing standards of care for TGNC adults and clear frameworks for how to conduct patient assessments for initiation of HRT. However, biomedical interventions and practice recommendations for gender-affirming HRT for older TGNC adults are not comprehensively or explicitly described. Practice recommendations herein examine assessment, risk, benefit, and treatment for older TGNC… 

References

SHOWING 1-10 OF 41 REFERENCES

Factors Associated with Gender-Affirming Surgery and Age of Hormone Therapy Initiation Among Transgender Adults

A retrospective review of electronic health record data from a random sample of 201 transgender patients who presented for primary care between July 1, 2010 and June 30, 2015 extends the understanding of prevalence and factors associated with gender-affirming treatments among transgender adults seeking primary care.

Hormone Therapy in Adults: Suggested Revisions to the Sixth Version of the Standards of Care

The current Standards of Care for Gender Identity Disorders—Sixth Version provides a general overview of the risks and effects of adult hormone therapy, but at present offers limited guidance for the medical provider as to how best to execute this critical intervention.

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management.

Use of the Informed Consent Model in the Provision of Cross-Sex Hormone Therapy: A Survey of the Practices of Selected Clinics

Assessment of practice characteristics and potential legal risks to clinics utilizing the IC care model and assess for any known cases of regret by patients with respect to csHT found no related legal actions.

Care of the elderly transgender patient

  • R. Ettner
  • Medicine
    Current opinion in endocrinology, diabetes, and obesity
  • 2013
It is important that guidelines for appropriate and sensitive care be established for the elderly transgender patient, as this population is proliferating due to media attention and greater access to care.

Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.

MtoF should not be treated with oral ethinyl estradiol, and transdermal estrogens are probably safer than oral estrogens, and pre-existing cardiovascular risks should be taken into consideration when prescribing and choosing the type of estrogens in cross-sex hormone administration (oral vs transDermal).

Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis

Low‐quality evidence suggests that sex steroid therapy may increase LDL‐C and TG levels and decrease HDL‐C level in FTM individuals, whereas oral estrogens may increase TG levels in MTF individuals.

Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7

This version of the SOC recognizes that treatment for gender dysphoria has become more individualized, and can be used to help patients consider the full range of health services open to them, in accordance with their clinical needs and goals for gender expression.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.